Search clinical trials for: anacetrapib

Total 16 results

Cambridge University Hospitals NHS Foundation Trust
British Heart Foundation Cambridge Centre of Excellence

Completed

The Effect of Anacetrapib on Vascular Function and Arterial Stiffness (REVEAL-Vasc)

Atherosclerotic Cardiovascular Disease | Vascular Disease

United Kingdom
University of Oxford
Merck Sharp & Dohme LLC

Active, not recruiting

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL)

Atherosclerotic Cardiovascular Disease

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) (REALIZE)

Hyperlipoproteinemia Type II | Hypercholesterolemia, Familial
Merck Sharp & Dohme LLC

Completed

Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019) (DEFINE)

Coronary Heart Disease (CHD) | CHD Risk-Equivalent Disease
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)

Heterozygous Familial Hypercholesterolemia (HeFH)
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)

Hyperlipoproteinemia Type II | Homozygous Familial Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

MK0859 Dose-Ranging Study (0859-003)

Hypercholesterolemia | Mixed Hyperlipemia
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)

Ambulatory Blood Pressure
Merck Sharp & Dohme LLC

Completed

A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)

Hypercholesterolemia | Hyperlipidemia

3

Subscribe